Skip to content
Bored Studies
RecruitingPhase 3

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Regeneron Pharmaceuticals · NCT07015905

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
2000
US sites recruiting
18
Study start
June 25, 2025
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery.

The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Being studied: REGN7508; Apixaban; Enoxaparin; Placebo

Conditions: Venous Thromboembolism (VTE)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Is undergoing a primary elective unilateral TKA
  • Is in good health based on laboratory safety testing as described in the protocol
  • Body weight ≤130 kg at screening visit as described in the protocol

Key Exclusion Criteria

  • Any condition that, as assessed by the investigator, may confound the results of the study or pose an additional risk to the participant by study participation
  • History of bleeding in the 6 months prior to randomization requiring hospitalization or transfusion as described in the protocol
  • History of thromboembolic disease or thrombophilia
  • History of major surgery, including brain, spinal, or ocular, or major trauma within approximately the past 6 months prior to randomization
  • Has an estimated Glomerular Filtration Rate (GFR) of \<30 mL/min/1.73 m2 at the screening visit as described in the protocol

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Recruiting US locations

Study contacts (from the official record)

  • Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis… (NCT07015905) | Bored Studies